Implementation of Actinic Keratosis Guideline Among General Practitioners.

Status Active, not recruiting

Clinical Trial Summary

This study investigates 5-fluorouracil cream prescription trends by general practitioners for the treatment of field changes of actinic keratosis over the years 2016-2021. The aim is to analyse whether the publication of the multidisciplinary guideline on suspect skin lesions for general practitioners in 2017 has made an impact in the prescribing behaviour of general practitioners.

Clinical Trial Description

Actinic keratosis is the most common epithelial precancerous lesion among the Caucasian race. With an increase in prevalence worldwide due to an aging population and rise of ultraviolet exposure actinic keratosis are among the most frequently encountered skin lesions in clinical practice. Both dermatologists and general practitioners are increasingly confronted with actinic keratosis, entailing to higher healthcare costs and time burden. There are many therapeutic modalities for the treatment of actinic keratosis, depending on multiple factors such as distribution, characteristics, patient preference, side effects, availability and costs. Treatment options can be divided into: lesion directed therapy en field directed therapy. Both dermatologists and general practitioners can treat actinic keratosis and 5-fluorouracil cream can also be prescribed by general practitioners. The objective of this study was to investigate 5-fluorouracil cream prescription trends by general practitioner for the treatment of field changes of actinic keratosis over the years 2016-2021. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05976048
Study type	Observational
Source	Maastricht University Medical Center
Contact
Status	Active, not recruiting
Phase
Start date	March 1, 2020
Completion date	September 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03575780` - Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis	Phase 1
Completed	`NCT04085367` - Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face	Phase 3
Recruiting	`NCT05937529` - Impact of Madecassoside and 5 % Panthenol Cream in Post Photodynamic Therapy for Actinic Keratosis	N/A
Completed	`NCT02520700` - A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses	N/A
Terminated	`NCT01538901` - Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients	Phase 4
Completed	`NCT01354717` - Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo	Phase 3
Completed	`NCT00742391` - A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations	Phase 3
Completed	`NCT03285477` - A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp	Phase 3
Suspended	`NCT03963102` - Duration of Ameluz Application in Acral Actinic Keratoses Response	Phase 4
Not yet recruiting	`NCT06026358` - Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands	Phase 4
Completed	`NCT02622594` - Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times	Phase 4
Completed	`NCT00774787` - Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses	Phase 4
Completed	`NCT00786994` - The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses	Phase 2
Completed	`NCT00544258` - Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005	Phase 1
Completed	`NCT04024579` - Treatment of Actinic Keratosis With 5% KOH Solution
Completed	`NCT04843553` - Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients	Early Phase 1
Completed	`NCT03315286` - Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure	N/A
Completed	`NCT03279328` - Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents	Phase 4
Completed	`NCT02062853` - Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video	N/A
Terminated	`NCT01532453` - Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients	Phase 3